.Monopar Rehabs is actually recouping a drug from the scrap heap of AstraZeneca’s uncommon disease pipe. It has licensed ALXN-1840, an applicant for the treatment
Read moreAZ lays out AI-enabled TROP2 biomarker approach for Daiichi ADC
.AstraZeneca has used artificial intelligence to develop a special biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), planning to separate the antibody-drug conjugate (ADC)
Read moreAN 2 one-halfs head count, quits period 3 trial after data disappoint
.AN2 Rehabs is reviewing its own organization in action to dull midphase records, pledging to give up half its own employees as well as cease
Read moreALX’s fizzling CD47 action price delivers supply spiraling down
.ALX Oncology’s period 2 stomach cancer cells action cost has actually weakened. After observing its own CD47 blocker easily beat control over the initial half
Read moreAC Immune sees ‘spots’ possible in Alzheimer’s medication data
.After greater than twenty years of service neurodegenerative diseases, Swiss biotech air conditioner Immune cases it could possibly possess a game changer on its own
Read more